The finger-prick alternative may help diabetic patients more effectively monitor their condition.
An adequate structure must be in place to support a QMS.
Severity of harm is what ultimately matters most in terms of protecting patients from the consequences of use errors.
Some key factors that companies should not overlook when developing drug-device products.
The agreement will create a pure-play infusion therapy company.
Some insights on integrating stability testing requirements into a device organization’s plan to make combination products.
Highlights include leveraging big data, streamlining clinical trial design, reducing healthcare-associated infections and toughening up on cybersecurity.
In the medical device world, “sustainability” is more than a buzzword—it’s an economic and social duty.
The IN.PACT Admiral device will provide a new treatment option for PAD patients.
Human factors engineering and the tools companies can leverage will get way more sophisticated.